Validation of a new fibrinolysis assay for thrombelastometry on the ROTEM® device

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON21605

Enrollment

200

Registered

2021-07-28

Start date

2021-07-28

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis (with/without DIC), Liver impairment (Child-Pugh A/B/C), Patientgroups in which an altered hemostatic balance can be expected, like patients treated for hematological malignancies who have severe thrombocytopenia

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: The population consist of all in hospital adult (= 18 years old) patients at the Maastricht University Medical Centre. 20-30 patients of each group will be asked informed consent for blood withdrawal for this in vitro measurement on the ROTEM® device. The population consist of the following patient groups: - Sepsis (with/without DIC) - Liver impairment (Child-Pugh A/B/C) - Patientgroups in which an altered hemostatic balance can be expected, like patients treated for hematological malignancies who have severe thrombocytopenia

Exclusion criteria

Exclusion criteria: temperature >38,0°C, sepsis, active bleeding, splenomegaly or use of anticoagulation medication.

Design outcomes

Primary

Measure	Time frame
Validation of a newly developed fibrinolysis assay on the ROTEM® device in multiple groups of patients with different pathological entities.	—

Secondary

Measure	Time frame
Effects of platelet transfusion on fibrinolysis assays in chemotherapy induced thrombocytopenic patients	—

Contacts

Public ContactFloor Heubel-Moenen

MUMC+

floor.moenen@mumc.nl0433876543

Outcome results